Context: The appointment of the M6 is crucial because it is an indicator of the prognosis of the evolution of the care and the decision-making on the continuation of the AntiRetroViral Treatment. Objective: The objective of this study is therefore to present the virological and molecular profile of People Living with HIV under treatment with Dolutegravir 6 months after being put on ART in Kinshasa. Methods: The present study is a cross-sectional view at the sixth month of a prospective cohort to determine the virological and molecular profile of People Living with HIV (PLHIV) after 6 months of ART based on Dolutegravir (DTG) in Kinshasa. A sample of 5 mL of blood was taken from all HIV patients included. The collection of biological data was carried out under the same conditions as at inclusion. After extraction, Quantitative Real-Time PCR was carried out to determine the quantity of HIV RNA in the samples according to the protocols previously described. Reverse Transcription PCR (RT-PCR) and Nested PCR were carried out to amplify the regions of interest for Protease and Reverse Transcriptase for sequencing. Results: The median VL value was 2.92 log10 RNA copies/mL. With 17.75% of patients experiencing major failure of first-line treatment. Subtype A is dominant with 13 cases (20.98%); followed by CRF_02AG (16.13%), subtypes C (14.52%), D (9.68%) and K (6.45%). The K65R (3 cases), T69P/N (6 cases), K70R (9 cases) and M184V (8 cases) mutations were listed as existing mutations for Nucleotide Reverse Transcriptase Inhibitors. Conclusion: After 6 months of ART, 59.67% of People Living with HIV on Tenofovir-Lamivudine-Dolutegravir is in therapeutic success while 40.33% are in a state of treatment failure. Subtype A remains dominant in the population of PLHIV. Resistance mutations were detected for Lamivudine and Tenofovir, but none for Dolutegravir.
References
[1]
Estill, J., Marsh, K., Autenrieth, C. and Ford, N. (2020) How to Achieve the Global 90-90-90 Target by 2020 in Sub-Saharan Africa? A Mathematical Modelling Study. Tropical Medicine & International Health, 23, 1223-1230. https://doi.org/10.1111/tmi.13145
[2]
Bain, L.E., Nkoke, C. and Noubiap, J.J.N. (2020) UNAIDS 90-90-90 Targets to End the AIDS Epidemic by 2020 Are Not Realistic: Comment on “Can the UNAIDS 90-90-90 Target Be Achieved? A Systematic Analysis of National HIV Treatment Cascades”. BMJ Global Health, 2, e000227. https://doi.org/10.1136/bmjgh-2016-000227
[3]
Genet, A., Mekonnen, Z., Yizengaw, E. and Mekonnen, D. (2021) First Line Antiretroviral Treatment Failure and Associated Factors among People Living with HIV in Northwest Ethiopia. African Health Sciences, 21, 263-272. https://doi.org/10.4314/ahs.v21i1.34
[4]
Nansseu, J.R.N. and Bigna, J.J.R. (2017) Antiretroviral Therapy Related Adverse Effects: Can Sub-Saharan Africa Cope with the New “Test and Treat” Policy of the World Health Organization? Infectious Diseases of Poverty, 6, Article No. 24. https://doi.org/10.1186/s40249-017-0240-3
[5]
United Nations AIDS Program (UNAIDS) (2020) Country Factsheets: Democratic Republic of the Congo. https://www.unaids.org/en/regionscountries/countries/democraticrepublicofthecongo
[6]
Programme Nation de Lutte contre la VIH/SIDA et les ISTs, Ministère de la Santé Publique, République Démocratique du Congo (2016) Guide de prise en charge intégrée du VIH/SIDA en République Démocratique du Congo. Révision de Septembre 2016.
[7]
Ministère du plan et suivi de la mise en œuvre de la révolution de la modernité et Ministère de la Santé Publique, République Démocratique du Congo. Rapport synthèse de l’Enquête Démographique et santé (EDS-RDC II), 2013-2014.
[8]
Bongenya, I.B., Tshinguta, L.C., Sombo, A.S.M.T., Bumoko, M.M.G., Kabengele, O.B., Mesia, K.G. and Kamangu, N.E. (2023) Virological and Molecular Profile of People Living with the Human Immunodeficiency Virus starting Dolutegravir Based Antiretroviral Treatment in Kinshasa, Democratic Republic of Congo. World Journal of AIDS, 13, 83-94. https://doi.org/10.4236/wja.2023.133008
[9]
(2010) QIAGEN: QIAamp® RNA Mini and Blood Mini Handbook. 3rd Edition.
[10]
Kamangu, N.E., Chatté, A., Boreux, R., Kalala, L.R., Mvumbi, L.G., De Mol, P., Vaira, D. and Hayette, M.P. (2014) Implementation of an In-House Quantitative Real-Time PCR for Determination of HIV Viral Load in Kinshasa. Open Access Library Journal, 1, e855. https://doi.org/10.4236/oalib.1100855
[11]
Kamangu, N.E., Chatté, A., Boreux, R., Susin, F., Kalala, L.R., Mvumbi, L.G., De Mol, P., Hayette, M.P. and Vaira, D. (2015) Comparison of an In-House Quantitative PCR and COBAS Ampliprep/TaqMan Roche for Determination of Viral Load for HIV Type 1 Non-B. Open Access Library Journal, 2, e1402. https://doi.org/10.4236/oalib.1101402
[12]
Kamangu, N.E., Wumba, D.M.R., Situakibanza, N.T.H., Lukusa, T.P., Kapend, K.L., Mvumbi, L.G., Hayette, M.P. and Kalala, L.R. (2018) Molecular Epidemiology of Human Immunodeficiency Virus Type 1 and Therapeutic Monitoring of Patients Treated in Kinshasa/Democratic Republic of the Congo. International Journal of HIV and Aids Research, 2, 6-11.
[13]
Kamangu, E.N. (2022) Caractérisation Moléculaire du VIH-1 à Kinshasa: Caractérisation Moléculaire et Suivi Thérapeutique des Patients pris en charge à Kinshasa, RD Congo. Editions Universitaires Européennes, Chisinau.
[14]
Losenga, L.O., Dikati, N.M., Bongenya, B.I., Ntumba, T.K., Booto, G.I., Dembo, R.D., Selenge, S.M., Nonga, J.E., Kabamba, C.A., Sombo, M.-T.A.S., Bumoko, G.M.M. and Kamangu, E.N. (2022) Sociodemographic and Anthropometric Profile of People Living with Human Immunodeficiency Virus Starting Treatment in Kinshasa, Democratic Republic of the Congo. Open Access Library Journal, 9, e9056. https://doi.org/10.4236/oalib.1109056
[15]
Bongenya, B.I., Kabengele, B.O., Sombo, M.T.A.S., Bumoko, G.M.M., Situakibanza, H.N.T., Kodondi, F.K.K., Mesia, G.K., Lusakibanza, M.M., Kayembe, J.M.N., Mvumbi, G.L., Buassa, B.B., Kalala, R.L. and Kamangu, E.N. (2023) Profile of People Living with Human Immunodeficiency Virus Initiating Treatment in the Dolutegravir Era in Kinshasa, Democratic Republic of Congo. World Journal of AIDS, 13, 95-115. https://doi.org/10.4236/wja.2023.133009
[16]
Kamangu, E.N., Bulanda, B.I., Bongenia, B.I., Botomwito, H.T., Mvumbi, G.L., De Mol, P., Vaira, D., Hayette, M.-P. and Kalala, R.L. (2015) Virological Profile of Patients Infected with HIV Starting Antiretroviral Treatment in Kinshasa. Open Access Library Journal, 2, e1564. https://doi.org/10.4236/oalib.1101564
[17]
Kamangu, N.E., Kawila, M.E., Mukumbi, H. and Mvumbi, L.G. (2012) Estimated Rates of Treatment Failure in First-Line Antiretroviral Treatment in Kinshasa: Case of the ACS AMO-Congo. International Journal of Collaborative Research on Internal Medicine & Public Health, 4, 885-891.
[18]
Kamangu, E.N. (2020) Diversité Génétique du VIH à Kinshasa, République Démocratique du Congo: Défis d’une dynamique évolutive. Editions Universitaires Européennes, Chisinau.
[19]
Vitoria, M., Hill, A., Ford, N., Doherty, M., Clayden, P., Venter, F., Ripin, D., Flexner, C. and Domanico, P.L. (2018) The Transition to Dolutegravir and Other New Antiretrovirals in Low-Income and Middle-Income Countries: What Are the Issues? AIDS, 32, 1551-1561. https://doi.org/10.1097/QAD.0000000000001845
[20]
Inzaule, S.C., Hamers, R.L., Doherty, M., Shafer, R.W., Bertagnolio, S. and Rinke de Wit, T.F. (2019) Curbing the Rise of HIV Drug Resistance in Low-Income and Middle-Income Countries: The Role of Dolutegravir Containing Regimens. The Lancet Infectious Diseases, 19, e246-e252. https://doi.org/10.1016/S1473-3099(18)30710-2
[21]
Kamangu, N.E. (2018) Frequencies of Molecular Markers of Resistance to Non-Nucleotide Inhibitors of Reverse Transcriptase in Treatment-Naive HIV-Infected Patients in Kinshasa. SciFed Journal of AIDS & HIV Research, 2, Article ID: 1000011.
